GlassScriptPhysician profile
James D Colleen
NPI 1265512073
$1,217.02
in general payments reported to CMS, 2019-2025
16 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $265 · 2022: $241 · 2023: $175 · 2024: $307 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $297.87 | 2024-2025 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Daiichi Sankyo INC. | $188.59 | 2021-2022 | |
| Stryker Corporation | $148.46 | 2024 | |
| Astellas Pharma US INC | $133.27 | 2021-2025 | Veozah |
| Abbvie INC. | $95.18 | 2021-2023 | Liletta |
| Myovant Sciences INC. | $86.65 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $74.17 | 2023 | Myfembree |
| Millicent US INC | $38.19 | 2021-2025 | Intrarosa, Femring |
| Pfizer INC. | $34.89 | 2022-2023 | |
| Biogen, INC. | $28.12 | 2025 | Zurzuvae |
| Boston Scientific Corporation | $16.90 | 2023 | Solyx Sis System |
| Lupin INC. | $16.12 | 2021 | |
| Mayne Pharma Commercial LLC | $15.68 | 2023 | |
| Coloplast Corp | $14.87 | 2023 | Saffron |
| Exeltis, USA INC. | $14.37 | 2025 | Slynd |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Colleen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.